EWTX Stock Analysis: Buy, Sell, or Hold?
EWTX - Edgewise Therapeutics, Inc. Common Stock
$41.52
2.69 (6.93%)
▲
5d:
+22.3%
30d:
+26.97%
90d:
+35.51%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.7/10
Get Alerted When EWTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: EWTX is 14.7% above its trading range ($36.21). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: EWTX is 14.7% above its trading range ($36.21). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: EWTX is currently trading at $41.52, which is considered extended relative to its 30-day fair value range of $32.57 to $36.21.
Technical Outlook: Technically, EWTX is in a uptrend. The price is approaching resistance at $39.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.9% recently.
Market Sentiment: EWTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $48.17 (+24.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EWTX is in a uptrend. The price is approaching resistance at $39.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.9% recently.
Market Sentiment: EWTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $48.17 (+24.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$32.57 -
$36.21
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+14.7% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.9%)
- BULLISH: Trading 24.0% below Wall St target ($48.17)
Trading Range Analysis
30-Day Trading Range
$32.57 -
$36.21
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$30.84
Resistance Level
$39.34
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-27.25
Wall Street Target
$48.17
(+24.0%)
Share & Embed Analysis
Last updated: June 24, 2026 11:08 AM ET
Data refreshes hourly during market hours. Next update: 12:08 PM
Data refreshes hourly during market hours. Next update: 12:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EWTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Joanne M Donovan
SELL
28662 shares
2026-04-01
Badreddin Edris
SELL
115471 shares
2026-01-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
